Stock Research Monitor: MASI, MDT, and MYO

LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on MDXG sign up now at www.wallstequities.com/registration. WallStEquities.com has selected the following stocks for review this morning: Masimo Corp. (NASDAQ: MASI), Medtronic PLC (NYSE: MDT), MiMedx Group Inc. (NASDAQ: MDXG), and Myomo Inc. (NYSE AMER: MYO). Companies in the Medical Appliances and Equipment space are engaged in the manufacture of medical instruments, such as dental and surgical appliances. They tend to offer below-average dividend yields when compared to the wider market. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Masimo

Shares in Irvine, California headquartered Masimo Corp. ended Friday's session 0.27% lower at $101.27. A total volume of 675,320 shares was traded, which was above their three months average volume of 438,370 shares. The stock has advanced 5.05% in the last month, 16.47% over the previous three months, and 11.47% over the past year. The Company's shares are trading 7.02% above their 50-day moving average and 14.22% above their 200-day moving average. Moreover, shares of Masimo, which develops, manufactures, and markets noninvasive monitoring technologies worldwide, have a Relative Strength Index (RSI) of 61.52.

On June 11th, 2018, Masimo announced the findings of an abstract presented at Euroanaesthesia 2018 in which researchers compared Masimo Patient State Index (PSi), a processed EEG parameter provided by SedLine® brain function monitoring (in this study, first generation SedLine), to Medtronic Bispectral Index in monitoring the depth of anesthesia of two groups of patients. The researchers found "excellent" agreement between the two methods as well as similar sevoflurane consumption and found that PSi 1.0 was less affected by electrocautery. Get the full research report on MASI for free by clicking below at:

www.wallstequities.com/registration/?symbol=MASI


Medtronic

Dublin, Ireland headquartered Medtronic PLC's shares rose 0.24%, closing the day at $86.78. A total volume of 6.44 million shares was traded, which was higher than their three months average volume of 4.84 million shares. The stock has advanced 1.44% in the last month and 6.75% in the previous three months. The Company's shares are trading 4.27% and 6.36% above their 50-day and 200-day moving averages, respectively. Additionally, shares of Medtronic, which manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide, have an RSI of 56.81.

On June 06th, 2018, research firm William Blair resumed its 'Market Perform' rating on the Company's stock.

On June 13th, 2018, Medtronic announced that the US FDA recently approved the Company's state-of-the art Deep Brain Stimulation Clinician Programmer and ActivaTMProgramming Application, which followed closely on the recent achievement of CE Mark this past March. The ActivaTMProgramming Application has been uniquely designed with the input of over a hundred clinicians from around the world and is managed on the Samsung Galaxy Tab S2 tablet interface. To experience our free membership services anytime/ anywhere and access the free report on MDT, click to register at:


www.wallstequities.com/registration/?symbol=MDT


MiMedx Group

Last Friday, shares in Marietta, Georgia headquartered MiMedx Group Inc. gained 4.64%, closing the session at $5.64. The stock recorded a trading volume of 7.07 million shares, which was higher than its three months average volume of 2.67 million shares. The Company's shares are trading 23.88% below their 50-day moving average. Furthermore, shares of MiMedx Group, which develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare, have an RSI of 32.05.

On June 07th, 2018, MiMedx Group announced that John D. Harris has joined as its Senior Vice President of International. Prior to joining the Company, Mr. Harris served as Vice President and General Manager of Cytori Therapeutics, where he had P&L responsibility for their global product portfolio. Join our big investor community at Wall St. Equities today and get your free report on MDXG at:

www.wallstequities.com/registration/?symbol=MDXG


Myomo

Cambridge, Massachusetts headquartered Myomo Inc.'s stock finished the session 2.22% lower at $3.08 with a total trading volume of 73,502 shares. The stock is trading below their 50-day moving average by 10.33%. Shares of the Company, which designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the US, have an RSI of 43.32.

On June 06th, 2018, Myomo announced that its MyoPro myoelectric arm orthosis (powered brace) is now available to adolescent patients with paralyzed or weakened arms. MyoPro is the only lightweight wearable device on the market that can help restore substantial functionality in the arms and hands of individuals who are suffering from the effects of a neuromuscular disease or injury. Know more about MYO in our free research coverage at:

www.wallstequities.com/registration/?symbol=MYO

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities